• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 28, 2018

View Archived Issues

Clinical data for Aug. 27, 2018

Read More

Regulatory front

Before seeking new regulatory authorities for the 340B program, the U.S. Health Resources and Services Administration (HRSA) needs to use the authority it already has, the Democrat and Republican leadership of the Senate Health, Education, Labor and Pensions Committee and the House Energy & Commerce Committee said in a letter Monday to the agency.  Read More

Financings

Novaremed AG, of Basel, Switzerland, said it raised additional financing of CHF6 million (US$6.12 million) from existing shareholders and several new private investors via a rights offering, with pro-rata rights for existing shareholders. The proceeds will be used to prepare for a global phase IIb study of its lead compound, NRD.E1, a first-in-class, small molecule for patients suffering from diabetic neuropathic pain. Read More

Other news to note

Biocancell Ltd., of Cambridge, Mass., said it is changing its name to Anchiano Therapeutics and will now trade on the Tel Aviv Stock Exchange under the ticker symbol ANCN (formerly BICL). The company is focused on the discovery and development of therapies to treat cancer. It most advanced product candidate, inodiftagene vixteplasmid (BC-819), is in development as a treatment for non-muscle invasive bladder cancer. Read More

Biopharma companies lag general markets in August

As we head toward the Labor Day holiday weekend, the market performance of the sector's blue chip companies have so far failed to capitalize on their welcomed surge in valuation in July. As a result they are treading water this month with the value of the BioWorld Biopharmaceutical Index up a modest 0.5 percent at last Thursday's market close compared to a 1 percent increase in the Dow Jones Industrial Average and a 3 percent jump in value for the Nasdaq Composite index. (See BioWorld Biopharmaceutical index, page 8.) Read More

Prescient plans basket approach to targeting range of cancers

PERTH, Australia – After reporting positive data at the American Society of Clinical Oncology (ASCO) meeting for its Akt inhibitor in estrogen receptor (ER)-positive breast cancer, Melbourne-based Prescient Therapeutics Pty Ltd. is poised to carve out a niche for itself across a variety of cancers. Read More

Roche gets CNDA nod for Alecensa for ALK-positive NSCLC

HONG KONG – Roche Holding AG was granted a rapid approval from the China National Drug Administration (CNDA) for Alecensa (alectinib). The drug was greenlighted as a monotherapy treatment for patients with anaplastic lymphoma kinase (ALK)-positive, advanced non-small-cell lung cancer (NSCLC). Read More

World bracing for season, Sanofi ships new flu shots; confident in strains choice

The long quest for a universal influenza vaccine may soon bear fruit, David Greenberg, associate vice president and regional medical head in North America for Sanofi Pasteur, told BioWorld. "We're moving in the right direction," he said, adding that "it's been tough from a research perspective," though his group – the vaccine division of Paris-based Sanofi SA – has been working internally and with collaborators that include the University of Georgia and others. "Progress is definitely being made toward a vaccine that would provide broader protection. I think it's likely that a candidate vaccine would be going into clinical trials in the next year or two. The testing at least is not a decade away, the way we used to talk about it some years ago." Read More

Pfizer's phase III tafamidis study shows reduced ATTR-CM mortality, hospitalization rates

New data from a phase III study of Pfizer Inc.'s tafamidis in treating the rare and fatal disorder transthyretin amyloid cardiomyopathy (ATTR-CM) showed a 30 percent reduction in the risk of mortality and 32 percent reduction in the rate of cardiovascular-related hospitalizations vs. placebo. The data, presented at the European Society of Cardiology Congress in Munich and simultaneously published online in The New England Journal of Medicine, are likely to lay the groundwork for an upcoming U.S. regulatory filing for the drug.  Read More

New complexities uncovered in inflammation's link to Alzheimer's

In findings that underscore the complex roles of inflammation in the brain, researchers have reported that in a transgenic mouse model of Alzheimer's disease (AD), proinflammatory cytokines protected the animals from developing seizures that were severe enough to kill the animals. Read More

Tetraphase to take FDA-approved Xerava to market in fourth quarter to treat cIAI

Tetraphase Pharmaceuticals Inc. turned the commercial corner with FDA approval of Xerava (eravacycline) to treat complicated intra-abdominal infections, or cIAI. Read More

Regulatory actions for Aug. 27, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe